Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of SOF/VEL/VOX in Prior Gilead HCV Study Participants
NCT03118843Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of sofosbuvir + velpatasvir + voxilaprevir in hepatitis C (HCV), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event at 12 weeks. Started Apr 2017; status: completed.
02
Drugs
sofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03118843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118843.